News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Oasmia Initiates Clinical Program With Paclical® in Metastatic Breast Cancer


5/6/2013 9:18:59 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Uppsala, Sweden, 2013-05-06 14:00 CEST (GLOBE NEWSWIRE) -- The active substance of Paclical, paclitaxel, is used in the treatment of breast cancer, often in combination with e.g. hormonal treatment. Cytostatic treatment every third week has been clinical practice for an extended period of time. Adverse effects such as nausea and vomiting occur, but it is a significant decrease in the number of white blood cells that might lead to dose reduction and hence reduced effect of the treatment. The hypothesis is that weekly treatment with a lower dose would affect the white blood cells less than the tumour cells, thus provide a treatment with less adverse effect but with a maintained efficacy compared to 3-week treatment. Preliminary results showed that the treatment is well tolerated, and it was decided to initiate the program.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
Oasmia
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES